Safety and efficacy of Durvalumab with or without Tremelimumab in patients with PD-L1–low/negative recurrent or metastatic HNSCC: The phase 2 CONDOR randomized clinical trrial

Lillian L. Siu, Caroline Even, Ricard Mesía, Eva Remenar, Amaury Daste, Jean-Pierre Delord, Jürgen Krauss, Nabil F. Saba, Lisle Nabell, Neal E. Ready, Irene Braña, Nuria Kotecki, Dan P. Zandberg, Jill Gilbert, Hesham Mehanna, Marcelo Bonomi, Anthony Jarkowski, Giovanni Mellilo, Jon M. Armstrong, Sophie WildsmithJérôme Fayette

Research output: Contribution to journal › Article › peer-review

93 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety and efficacy of Durvalumab with or without Tremelimumab in patients with PD-L1–low/negative recurrent or metastatic HNSCC: The phase 2 CONDOR randomized clinical trrial'. Together they form a unique fingerprint.

Medicine & Life Sciences